The Health Benefits of SMOKING CESSATION

a report of the Surgeon General

1990
Suggested Citation

The Honorable Thomas S. Foley  
Speaker of the House of Representatives  
Washington, D.C. 20515  

Dear Mr. Speaker:  

It is my pleasure to transmit to the Congress the 1990 Surgeon General's Report on the health consequences of smoking as mandated by Section 8(a) of the Public Health Cigarette Smoking Act of 1969 (Pub. L. 91-222). The report was prepared by the Centers for Disease Control's Office on Smoking and Health.

This report, entitled The Health Benefits of Smoking Cessation, examines how an individual's risk of smoking-related diseases declines after quitting smoking. The evidence is overwhelming that smoking cessation has major and immediate health benefits for men and women of all ages. Smoking cessation increases overall life expectancy and reduces the risk of lung cancer, other cancers, heart attack, stroke, and chronic lung diseases such as emphysema. The health benefits of smoking cessation far exceed any risks from the average 5-pound weight gain or any adverse psychological effects that may follow quitting.

Cigarette smoking is the most important preventable cause of death in our society. It is responsible for approximately 360,000 deaths each year in the United States, or more than one of every six deaths. We must do all we can to prevent young people from taking up this deadly addiction, and we must help smokers quit. Given the enormous benefits of smoking cessation, and the fact that good smoking cessation programs can achieve abstinence rates of 20 to 40 percent at one-year followup, these programs are likely to be extremely cost-effective compared with other preventive or curative services. Therefore, I would encourage health insurers to provide payment for smoking cessation treatments that are shown to be effective. At a minimum, the treatment of nicotine addiction should be considered as favorably by third-party payers as treatment of alcoholism and illicit drug addiction.

This report should help convince all smokers of the compelling need to quit smoking.

Sincerely,

Louis W. Sullivan, M.D.  
Secretary

Enclosure
The Honorable Dan Quayle
President of the Senate
Washington, D.C. 20515

Dear Mr. President:

It is my pleasure to transmit to the Congress the 1990 Surgeon General's Report on the health consequences of smoking as mandated by Section 8(a) of the Public Health Cigarette Smoking Act of 1969 (Pub. L. 91-222). The report was prepared by the Centers for Disease Control's Office of Smoking and Health.

This report, entitled The Health Benefits of Smoking Cessation, examines how an individual's risk of smoking-related diseases declines after quitting smoking. The evidence is overwhelming that smoking cessation has major and immediate health benefits for men and women of all ages. Smoking cessation increases overall life expectancy and reduces the risk of lung cancer, other cancers, heart attack, stroke, and chronic lung disease such as emphysema. The health benefits of smoking cessation far exceed any gains from the average 5-pound weight gain or any adverse psychological effects that may follow quitting.

Cigarette smoking is the most important preventable cause of death in our society. It is responsible for approximately 390,000 deaths each year in the United States, or more than one of every six deaths. We must do all we can to prevent young people from taking up this deadly addiction, and we must help smokers quit. Given the enormous benefits of smoking cessation, and the fact that good smoking cessation programs can achieve abstinence rates of 20 to 40 percent at one-year followup, these programs are likely to be extremely cost-effective compared with other preventive or curative services. Therefore, I would encourage health insurers to provide payment for smoking cessation treatments that are shown to be effective. At a minimum, the treatment of nicotine addiction should be considered as favorably by third-party payors as treatment of alcoholism and illicit drug addiction.

This report should help convince all smokers of the compelling need to quit smoking.

Sincerely,

Louis W. Sullivan, M.D.
Secretary

Enclosure
More than 38 million Americans have quit smoking cigarettes, and nearly half of all living adults who ever smoked have quit. Unfortunately, some 50 million Americans continue to smoke cigarettes, despite the many health education programs and anti-smoking campaigns that have been conducted during the past quarter century, despite the declining social acceptability of smoking, and despite the consequences of smoking to their health.

Twenty previous reports of the Surgeon General have reviewed the health effects of smoking. Scientific data are now available on the consequences of smoking cessation for most smoking-related diseases. Previous reports have considered some of these data, but this Report is the first to provide a comprehensive and unified review of this topic.

The major conclusions of this volume are:

1. Smoking cessation has major and immediate health benefits for men and women of all ages. Benefits apply to persons with and without smoking-related disease.
2. Former smokers live longer than continuing smokers. For example, persons who quit smoking before age 50 have one-half the risk of dying in the next 15 years compared with continuing smokers.
3. Smoking cessation decreases the risk of lung cancer, other cancers, heart attack, stroke, and chronic lung disease.
4. Women who stop smoking before pregnancy or during the first 3 to 4 months of pregnancy reduce their risk of having a low birthweight baby to that of women who never smoked.
5. The health benefits of smoking cessation far exceed any risks from the average 5-pound (2.3-kg) weight gain or any adverse psychological effects that may follow quitting.

With the long-standing evidence that smoking is extremely harmful to health and the mounting evidence that smoking cessation confers major health benefits, we remain faced with the task of developing effective strategies to curtail the use of tobacco. Two broad categories of intervention are available: prevention of smoking initiation among youth and smoking cessation. Resources for tobacco control are limited, and policymakers must decide how best to allocate those resources to smoking prevention and cessation.

The goal of public health is to intervene as early as possible to prevent disease, disability, and premature death. From that standpoint, prevention of smoking initiation
should be a major priority. More than 3,000 teenagers become regular smokers each day in the United States. Because of the strength of nicotine addiction, some have argued that public health efforts should focus on smoking prevention rather than smoking cessation. However, this need not be an "either-or" situation.

Public health practitioners have categorized interventions into primary, secondary, and tertiary prevention. Primary prevention generally refers to the elimination of risk factors for disease in asymptomatic persons. Secondary prevention is defined as the early detection and treatment of disease, and is practiced using tools such as Pap smears and blood pressure screening. Tertiary prevention consists of measures to reduce impairment, disability, and suffering in people with existing disease.

Smoking cessation falls under the category of primary prevention as does the prevention of smoking initiation. Smoking cessation meets the definition of primary prevention by reducing the risk of morbidity and premature mortality in asymptomatic people. In addition, parents who quit smoking reduce or eliminate the risk of passive-smoking-related disease among their children and reduce the probability that their children will become smokers. Thus, there should be no debate about the need for smoking prevention versus cessation—both are important.

Public awareness of the health effects of smoking has increased substantially through the years. Nevertheless, important gaps in public knowledge still exist. Some smokers may have failed to quit because of a lack of appreciation of the health hazards of smoking and the benefits of quitting. In the 1987 National Health Interview Survey of Cancer Epidemiology and Control, respondents were asked whether smoking increases the risk of various diseases (lung cancer, cancer of the mouth and throat, heart disease, emphysema, and chronic bronchitis) and whether smoking cessation reduces the risk. Thirty to forty percent of smokers either did not believe that smoking increases these risks or did not believe that cessation reduces these risks. These proportions correspond to 15 to 20 million smokers in the United States. Clearly, our efforts to educate the public on the health hazards of smoking and the benefits of quitting are not yet complete.

As we continue and intensify our efforts to inform the public of these findings, we must make available smoking cessation programs and services to those who need them. Although 90 percent of former smokers quit without using smoking cessation programs, counseling, or nicotine gum, smokers who do need this assistance should have it available. We endorse the view expressed in the Preface to the 1988 Surgeon General's Report that treatment of nicotine addiction should be considered at least as favorably by third party payors as treatment of alcoholism and illicit drug addiction. Good smoking cessation treatments can achieve abstinence rates of 20 to 40 percent at 1-year followup. These success rates, combined with the enormous health benefits of smoking cessation, would likely make payment for some smoking cessation treatments cost-beneficial. For example, research by the Centers for Disease Control suggests that a smoking cessation program offered to all pregnant smokers could save $5 for every dollar spent by preventing low birthweight associated neonatal intensive care and long-term care.
This Report should galvanize the health community to stress repeatedly at every opportunity the value of smoking cessation to the 50 million Americans who continue to smoke.

James O. Mason, M.D., Dr.P.H.
Assistant Secretary for Health
Public Health Service

William L. Roper, M.D.
Director
Centers for Disease Control
PREFACE

This Report of the Surgeon General is the 21st Report of the U.S. Public Health Service on the health consequences of smoking and the first issued during my tenure as Surgeon General. Whereas previous reports have focused on the health effects of smoking, this Report is devoted to the benefits of smoking cessation.

The public health impact of smoking is enormous. As documented in the 1989 Surgeon General's Report, an estimated 390,000 Americans die each year from diseases caused by smoking. This toll includes 115,000 deaths from heart disease; 106,000 from lung cancer; 31,600 from other cancers; 57,000 from chronic obstructive pulmonary disease; 27,500 from stroke; and 52,900 from other conditions related to smoking. More than one of every six deaths in the United States are caused by smoking. For more than a decade the Public Health Service has identified cigarette smoking as the most important preventable cause of death in our society.

It is clear, then, that the elimination of smoking would yield substantial benefits for public health. What are the benefits, however, for the individual smoker who quits? A large body of evidence has accumulated to address that question and derives from cohort and case-control studies, cross-sectional surveys, and clinical trials. In studies of the health effects of smoking cessation, persons classified as former smokers may include some current smokers; this misclassification is likely to cause an underestimation of the health benefits of quitting. Taken together, the evidence clearly indicates that smoking cessation has major and immediate health benefits for men and women of all ages.

Overall Benefits of Smoking Cessation

People who quit smoking live longer than those who continue to smoke. To what extent is a smoker's risk of premature death reduced after quitting smoking? The answer depends on several factors, including the number of years of smoking, the number of cigarettes smoked per day, and the presence or absence of disease at the time of quitting. Data from the American Cancer Society's Cancer Prevention Study II (CPS-II) were analyzed in this Report to estimate the risk of premature death in ex-smokers versus current smokers. These data show, for example, that persons who quit smoking before age 50 have one-half the risk of dying in the next 15 years compared with continuing smokers.

Smoking cessation increases life expectancy because it reduces the risk of dying from specific smoking-related diseases. One such disease is lung cancer, the most common cause of cancer death in both men and women. The risk of dying from lung cancer is
22 times higher among male smokers and 12 times higher among female smokers compared with people who have never smoked. The risk of lung cancer declines steadily in people who quit smoking; after 10 years of abstinence, the risk of lung cancer is about 30 to 50 percent of the risk for continuing smokers. Smoking cessation also reduces the risk of cancers of the larynx, oral cavity, esophagus, pancreas, and urinary bladder.

Coronary heart disease (CHD) is the leading cause of death in the United States. Smokers have about twice the risk of dying from CHD compared with lifetime nonsmokers. This excess risk is reduced by about half among ex-smokers after only 1 year of smoking abstinence and declines gradually thereafter. After 15 years of abstinence, the risk of CHD is similar to that of persons who have never smoked.

Compared with lifetime nonsmokers, smokers have about twice the risk of dying from stroke, the third leading cause of death in the United States. After quitting smoking, the risk of stroke returns to the level of people who have never smoked; in some studies, this reduction in risk has occurred within 5 years, but in others as long as 15 years of abstinence were required.

Cigarette smoking is the major cause of chronic obstructive pulmonary disease (COPD), the fifth leading cause of death in the United States. Smoking increases the risk of COPD by accelerating the age-related decline in lung function. With sustained abstinence from smoking, the rate of decline in lung function among former smokers returns to that of never smokers, thus reducing the risk of developing COPD.

Influenza and pneumonia represent the sixth leading cause of death in the United States. Cigarette smoking increases the risk of respiratory infections such as influenza, pneumonia, and bronchitis, and smoking cessation reduces the risk.

Cigarette smoking is a major cause of peripheral artery occlusive disease. This condition causes substantial mortality and morbidity; complications may include intermittent claudication, tissue ischemia and gangrene, and ultimately, loss of limb. Smoking cessation substantially reduces the risk of peripheral artery occlusive disease compared with continued smoking.

The mortality rate from abdominal aortic aneurysm is two to five times higher in current smokers than in never smokers. Former smokers have half the excess risk of dying from this condition relative to current smokers.

About 20 million Americans currently have, or have had, an ulcer of the stomach or duodenum. Smokers have an increased risk of developing gastric or duodenal ulcers, and this increased risk is reduced by quitting smoking.

Benefits at All Ages

According to a 1989 Gallup survey, the proportion of smokers who say they would like to give up smoking is lower for smokers aged 50 and older (57 percent) than for smokers aged 18–29 (68 percent) and 30–49 (67 percent). Older smokers may be less motivated to quit smoking because the highly motivated may have quit already at younger ages, leaving a relatively "hard-core" group of older smokers. But many long-term smokers may lack motivation to quit for other reasons. Some may believe they are no longer at risk of smoking-related diseases because they have already survived smoking for many years. Others may believe that any damage that may have
been caused by smoking is irreversible after decades of smoking. For similar reasons, many physicians may be less likely to counsel their older patients to quit.

CPS-II data were used to estimate the effects of quitting smoking at various ages on the cumulative risk of death during a fixed interval after cessation. The results show that the benefits of cessation extend to quitting at older ages. For example, a healthy man aged 60–64 who smokes 1 pack of cigarettes or more per day reduces his risk of dying during the next 15 years by 10 percent if he quits smoking.

These findings support the recommendations of the Surgeon General’s 1988 Workshop on Health Promotion and Aging for the development and dissemination of smoking cessation messages and interventions to older persons. I am pleased that a coalition of organizations and agencies is now working toward implementation of those recommendations, including the Centers for Disease Control; the National Cancer Institute; the National Heart, Lung, and Blood Institute; the Administration on Aging; the Department of Veterans Affairs; the Office of Disease Prevention and Health Promotion; the American Association of Retired Persons; and the Fox Chase Cancer Center. The major message of this campaign will be that it is never too late to quit smoking.

Two facts point to the urgent need for a strong smoking cessation campaign targeting older Americans: (1) 7 million smokers are aged 60 or older; and (2) smoking is a major risk factor for 6 of the 14 leading causes of death among those aged 60 and older, and is a complicating factor for 3 others.

Benefits for Smokers with Existing Disease

Many smokers who have already developed smoking-related disease or symptoms may be less motivated to quit because of a belief that the damage is already done. For the same reason, physicians may be less motivated to advise these patients to quit. However, the evidence reviewed in this Report shows that smoking cessation yields important health benefits to those who already suffer from smoking-related illness.

Among persons with diagnosed CHD, smoking cessation markedly reduces the risk of recurrent heart attack and cardiovascular death. In many studies, this reduction in risk has been 50 percent or more. Smoking cessation is the most important intervention in the management of peripheral artery occlusive disease; for patients with this condition, quitting smoking improves exercise tolerance, reduces the risk of amputation after peripheral artery surgery, and increases overall survival. Patients with gastric and duodenal ulcers who stop smoking improve their clinical course relative to smokers who continue to smoke. Although the benefits of smoking cessation among stroke patients have not been studied, it is reasonable to assume that quitting smoking reduces the risk of recurrent stroke just as it reduces the risk of recurrence of other cardiovascular events.

Even smokers who have already developed cancer may benefit from smoking cessation. A few studies have shown that persons who stopped smoking after diagnosis of cancer had a reduced risk of acquiring a second primary cancer compared with persons who continued to smoke. Although relevant data are sparse, longer survival might be expected among smokers with cancer or other serious illnesses if they stop
smoking. Smoking cessation reduces the risk of respiratory infections such as pneumonia, which are often the immediate causes of death in patients with an underlying chronic disease.

The important role of health care providers in counseling patients to quit smoking is well recognized. Health care providers should give smoking cessation advice and assistance to all patients who smoke, including those with existing illness.

**Benefits for the Fetus**

Maternal smoking is associated with several complications of pregnancy including abruptio placentae, placenta previa, bleeding during pregnancy, premature and prolonged rupture of the membranes, and preterm delivery. Maternal smoking retards fetal growth, causes an average reduction in birthweight of 200 g, and doubles the risk of having a low birthweight baby. Studies have shown a 25- to 50-percent higher rate of fetal and infant deaths among women who smoke during pregnancy compared with those who do not.

Women who stop smoking before becoming pregnant have infants of the same birthweight as those born to women who have never smoked. The same benefit accrues to women who quit smoking in the first 3 to 4 months of pregnancy and who remain abstinent throughout the remainder of pregnancy. Women who quit smoking at later stages of pregnancy, up to the 30th week of gestation, have infants with higher birthweight than do women who smoke throughout pregnancy.

Smoking is probably the most important modifiable cause of poor pregnancy outcome among women in the United States. Recent estimates suggest that the elimination of smoking during pregnancy could prevent about 5 percent of perinatal deaths, about 20 percent of low birthweight births, and about 8 percent of preterm deliveries in the United States. In groups with a high prevalence of smoking (e.g., women who have not completed high school), the elimination of smoking during pregnancy could prevent about 10 percent of perinatal deaths, about 35 percent of low birthweight births, and about 15 percent of preterm deliveries.

The prevalence of smoking during pregnancy has declined over time but remains unacceptably high. Approximately 30 percent of U.S. women who are cigarette smokers quit after recognition of pregnancy, and others quit later in pregnancy. However, about 25 percent of pregnant women in the United States smoke throughout pregnancy. A shocking statistic is that half of pregnant women who have not completed high school smoke throughout pregnancy. Many women who do not quit smoking during pregnancy reduce their daily cigarette consumption; however, reduced consumption without quitting may have little or no benefit for birthweight. Of the women who quit smoking during pregnancy, 70 percent resume smoking within 1 year of delivery.

Initiatives have been launched in the public and private sectors to reduce smoking during pregnancy. These programs should be expanded, and less educated pregnant women should be a special target of these efforts. Strategies need to be developed to address the problem of relapse after delivery.
Benefits for Infants and Children

As a pediatrician, I am particularly concerned about the effects of parental smoking on infants and children. Evidence reviewed in the 1986 Surgeon General’s Report, *The Health Consequences of Involuntary Smoking,* indicates that the children of parents who smoke, compared with the children of nonsmoking parents, have an increased frequency of respiratory infections such as pneumonia and bronchitis. Many studies have found a dose-response relationship between respiratory illness in children and their level of tobacco smoke exposure.

Several studies have shown that children exposed to tobacco smoke in the home are more likely to develop acute otitis media and persistent middle ear effusions. Middle ear disease imposes a substantial burden on the health care system. Otitis media is the most frequent diagnosis made by physicians who care for children. The myringotomy-and-tube procedure, used to treat otitis media in more than 1 million American children each year, is the most common minor surgical operation performed under general anesthesia.

The impact of smoking cessation during or after pregnancy on these associations has not been studied. However, the dose-response relationship between parental smoking and frequency of childhood respiratory infections suggests that smoking cessation during pregnancy and abstinence after delivery would eliminate most or all of the excess risk by eliminating most or all of the exposure.

If parents are unwilling to quit smoking for their own sake, I would urge them to quit for the sake of their children. Passive-smoking-induced infections in infants and young children can cause serious and even fatal illness. Moreover, children whose parents smoke are much more likely to become smokers themselves.

Smoking Cessation and Weight Gain

The fear of postcessation weight gain may discourage many smokers from trying to quit. The fear or occurrence of weight gain may precipitate relapse among many of those who already have quit. In the 1986 Adult Use of Tobacco Survey, current smokers who had tried to quit were asked to judge the importance of several possible reasons for their return to smoking. Twenty-seven percent reported that “actual weight gain” was a “very important” or “somewhat important” reason why they resumed smoking; 22 percent said that “the possibility of gaining weight” was an important reason for their relapse. Forty-seven percent of current smokers and 48 percent of former smokers agreed with the statement that “smoking helps control weight.”

Fifteen studies involving a total of 20,000 persons were reviewed in this Report to determine the likelihood of gaining weight and the average weight gain after quitting. Although four-fifths of smokers who quit gained weight after cessation, the average weight gain was only 5 pounds (2.3 kg). The average weight gain among subjects who continued to smoke was 1 pound. Thus, smoking cessation produces a 4-pound greater weight gain than that associated with continued smoking. This weight gain poses a minimal health risk. Moreover, evidence suggests that this small weight gain is accompanied by favorable changes in lipid profiles and in body fat distribution.
Smoking cessation programs and messages should emphasize that weight gain after quitting is small on average.

Not only is the average postcessation weight gain small, but the risk of large weight gain after quitting is extremely low. Less than 4 percent of those who quit smoking gain more than 20 pounds. Nevertheless, special advice and assistance should be available to the rare person who does gain considerable weight after quitting. For these individuals, the health benefits of cessation still occur, and weight control programs rather than smoking relapse should be implemented.

Increases in food intake and decreases in resting energy expenditure are largely responsible for postcessation weight gain. Thus, dietary advice and exercise should be helpful in preventing or reducing postcessation weight gain. Unfortunately, minor weight control modifications to smoking cessation programs do not generally yield beneficial effects in terms of reducing weight gain or increasing cessation rates. A few studies have investigated pharmacologic approaches to postcessation weight control: preliminary results are encouraging but more research is needed. High priority should be given to the development and evaluation of effective weight control programs that can be targeted in a cost-effective manner to those at greatest need of assistance.

**Psychological and Behavioral Consequences of Smoking Cessation**

Nicotine withdrawal symptoms include anxiety, irritability, frustration, anger, difficulty concentrating, increased appetite, and urges to smoke. With the possible exception of urges to smoke and increased appetite, these effects soon disappear. Nicotine withdrawal peaks in the first 1 to 2 days following cessation and subsides rapidly during the following weeks. With long-term abstinence, former smokers are likely to enjoy favorable psychological changes such as enhanced self-esteem and increased sense of self-control.

Although most nicotine withdrawal symptoms are short-lived, they often exert a strong influence on smokers' ability to quit and maintain abstinence. Nicotine withdrawal may discourage many smokers from trying to quit and may precipitate relapse among those who have recently quit. In the 1986 Adult Use of Tobacco Survey, 39 percent of current smokers reported that irritability was a "very important" or "somewhat important" reason why they resumed smoking after a previous quit attempt.

Smokers and ex-smokers should be counseled that adverse psychological effects of smoking subside rapidly over time. Smoking cessation materials and programs, nicotine replacement, exercise, stress management, and dietary counseling can help smokers cope with these symptoms until they abate, after which favorable psychological changes are likely to occur.

**Support for a Causal Association Between Smoking and Disease**

Tens of thousands of studies have documented the associations between cigarette smoking and a large number of serious diseases. It is safe to say that smoking represents the most extensively documented cause of disease ever investigated in the history of biomedical research.
Previous Surgeon General’s reports, in particular the landmark 1964 Report of the Surgeon General’s Advisory Committee on Smoking and Health and the 1982 Surgeon General’s Report on smoking and cancer, examined these associations with respect to the epidemiologic criteria for causality. These criteria include the consistency, strength, specificity, coherence, and temporal relationship of the association. Based on these criteria, previous reports have recognized a causal association between smoking and cancers of the lung, larynx, esophagus, and oral cavity; heart disease; stroke; peripheral artery occlusive disease; chronic obstructive pulmonary disease; and intrauterine growth retardation. This Surgeon General’s Report is the first to conclude that the evidence is now sufficient to identify cigarette smoking as a cause of cancer of the urinary bladder; the 1982 Report concluded that cigarette smoking is a contributing factor in the development of bladder cancer.

The causal nature of most of these associations was well established long before publication of this Report. Nevertheless, it is worth noting that the findings of this Report add even more weight to the evidence that these associations are causal. The criterion of coherence requires that descriptive epidemiologic findings on disease occurrence correlate with measures of exposure to the suspected agent. Coherence would predict that the increased risk of disease associated with an exposure would diminish or disappear after cessation of exposure. As this Report shows in great detail, the risks of most smoking-related diseases decrease after cessation and with increasing duration of abstinence.

Evidence on the risk of disease after smoking cessation is especially important for the understanding of smoking-and-disease associations of unclear causality. For example, cigarette smoking is associated with cancer of the uterine cervix, but this association is potentially confounded by unidentified factors (in particular by a sexually transmitted etiologic agent). The evidence reviewed in this Report indicates that former smokers experience a lower risk of cervical cancer than current smokers, even after adjusting for the social correlates of smoking and risk of sexually acquired infections. This diminution of risk after smoking cessation supports the hypothesis that smoking is a contributing cause of cervical cancer.

Conclusion

The Comprehensive Smoking Education Act of 1984 (Public Law 98–474) requires the rotation of four health warnings on cigarette packages and advertisements. One of those warnings reads, “SURGEON GENERAL’S WARNING: Quitting Smoking Now Greatly Reduces Serious Risks to Your Health.” The evidence reviewed in this Report confirms and expands that advice.

The health benefits of quitting smoking are immediate and substantial. They far exceed any risks from the average 5-pound weight gain or any adverse psychological effects that may follow quitting. The benefits extend to men and women, to the young and the old, to those who are sick and to those who are well. Smoking cessation represents the single most important step that smokers can take to enhance the length and quality of their lives.
Public opinion polls tell us that most smokers want to quit. This Report provides smokers with new and more powerful motivation to give up this self-destructive behavior.

Antonia C. Novello, M.D., M.P.H.
Surgeon General
ACKNOWLEDGMENTS

This Report was prepared by the Department of Health and Human Services under the general editorship of the Office on Smoking and Health, Ronald M. Davis, M.D., Director. The Managing Editor was Susan A. Hawk, Ed.M., M.S.

The scientific editors of the Report were:

Jonathan M. Samet, M.D. (Senior Scientific Editor). Professor of Medicine and Chief, Pulmonary Division, Department of Medicine and the New Mexico Tumor Registry, Cancer Center, University of New Mexico, Albuquerque, New Mexico

Ronald M. Davis, M.D., Director, Office on Smoking and Health, Center for Chronic Disease Prevention and Health Promotion (CCDPHP), Centers for Disease Control (CDC), Rockville, Maryland

Neil F. Grunberg, Ph.D., Professor, Department of Medical Psychology, Uniformed Services University of the Health Sciences, Bethesda, Maryland

Judith K. Ockene, Ph.D., Professor of Medicine, and Director, Division of Preventive and Behavioral Medicine, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts

Diana B. Petitti, M.D., M.P.H., Associate Professor, Department of Family and Community Medicine, University of California at San Francisco, School of Medicine, San Francisco, California

Walter C. Willett, M.D., Dr.P.H., Professor of Epidemiology and Nutrition, Harvard School of Public Health, and The Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham and Women’s Hospital, Boston, Massachusetts

The following individuals prepared draft chapters or portions of the Report:

Robert Anda, M.D., Epidemiologist, Office of Surveillance and Analysis, CCDPHP, CDC, Atlanta, Georgia

John Baron, M.D., Associate Professor of Medicine, Department of Medicine, Dartmouth Medical School, Hanover, New Hampshire

Tim Byers, M.D., M.P.H., Chief, Epidemiology Branch, Division of Nutrition, CCDPHP, CDC, Atlanta, Georgia

Arden G. Christen, D.D.S., M.S.D., M.A., Chairman, Professor, Department of Preventive and Community Dentistry, Indiana University School of Dentistry, Indianapolis, Indiana

Graham Colditz, Dr.P.H., Assistant Professor of Medicine, Harvard School of Public Health, and the Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham and Women’s Hospital, Boston, Massachusetts
Barbara Rimer, Dr.P.H., Director, Behavioral Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania
Mary Ann Salmon, Ph.D., Research Specialist, School of Social Work, C.A.R.E.S., University of North Carolina, Chapel Hill, North Carolina
Jonathan M. Samet, M.D. (Senior Scientific Editor), Professor of Medicine and Chief Pulmonary Division, Department of Medicine and the New Mexico Tumor Registry, Cancer Center, University of New Mexico, Albuquerque, New Mexico
David Savitz, Ph.D., Associate Professor, Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, North Carolina
Charles B. Sherman, M.D., Director, Pulmonary Division, Miriam Hospital, Providence, Rhode Island
Meir Stampfer, M.D., Dr.P.H., Associate Professor of Epidemiology, Harvard School of Public Health, and The Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham and Women’s Hospital, Boston, Massachusetts
Wayne F. Velicer, Ph.D., Professor, Co-Director, Cancer Prevention Research Unit, Department of Psychology, University of Rhode Island, Kingston, Rhode Island
Thomas Vogt, Ph.D., Principle Investigator, Center for Health Research, Portland, Oregon
Scott T. Weiss, M.D., Associate Professor, Harvard School of Public Health, and The Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham and Women’s Hospital, Boston, Massachusetts
Anna H. Wu-Williams, Ph.D., Associate Professor, Department of Preventive Medicine, University of Southern California, Los Angeles, California

The editors acknowledge with gratitude the following distinguished scientists, physicians, and others who lent their support in the development of this Report by coordinating manuscript preparation, contributing critical reviews, or assisting in other ways. In particular, the editors express appreciation to the American Cancer Society for making available data from its Cancer Prevention Study II.

David B. Abrams, Ph.D., Director, Division of Behavioral Medicine, The Miriam Hospital, Associate Professor, Psychiatry and Human Behavior, Brown University Program in Medicine, Providence, Rhode Island
Duane Alexander, M.D., Director, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland
David Bates, M.D., FRCP, FRCPC, FACP, FRSC, Professor Emeritus of Medicine, Department of Health Care, University of British Columbia, Vancouver, British Columbia
James S. Benson, Acting Commissioner, Food and Drug Administration, Rockville, Maryland
Trudy S. Berkowitz, Ph.D., Associate Professor, Department of Obstetrics, Gynecology, and Reproductive Science, Mount Sinai School of Medicine, New York, New York
Ruth Bonita, M.P.H., Ph.D., Masonic Senior Research Fellow, Geriatric Unit, University of Auckland, Auckland 9, New Zealand
Lester Breslow, M.D., M.P.H., Professor of Public Health and Director, Health Services Research, Division of Cancer Control, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California
Samuel Broder, M.D., Director, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
David Burns, M.D., Associate Professor, Pulmonary Division, Division of Pulmonary Medicine and Critical Care, University of California at San Diego Medical Center, San Diego, California
Benjamin Burrows, M.D., Director, Division of Respiratory Sciences, University of Arizona Health Sciences Center, University of Arizona School of Medicine, Tucson, Arizona
Jane Cauley, Dr.P.H., Assistant Professor of Epidemiology, Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania
Gregory N. Connolly, D.M.D., M.P.H., Director, Office on Nonsmoking and Health, Massachusetts Department of Public Health, Boston, Massachusetts
Thomas M. Cooper, D.D.S., Professor, University of Kentucky Medical Center, College of Dentistry, Lexington, Kentucky
Stephen Corbin, D.D.S., M.P.H., Policy Analyst, Disease Prevention, Center for Preventive Services (CPS), CDC, Bethesda, Maryland
K. Michael Cummings, Ph.D., M.P.H., Cancer Control and Epidemiology, Roswell Park Cancer Institute, Buffalo, New York
Joseph W. Cullen, Ph.D., Director, AMC Cancer Research Center, Denver, Colorado
Sir Richard Doll, ICRF Cancer Studies Unit, Oxford, United Kingdom
Virginia Ernst, Ph.D., Professor of Epidemiology, Department of Epidemiology and International Health, University of California, San Francisco, San Francisco, California
Jonathan E. Fielding, M.D., M.P.H., Vice President and Health Director, Johnson and Johnson Health Management, Inc., Santa Monica, California
Gary D. Friedman, M.D., M.S., Division of Research, Kaiser Permanente Medical Care Program, Northern California Region, Oakland, California
William Foege, M.D., Executive Director, The Carter Center of Emory University, Atlanta, Georgia
Lawrence J. Furman, D.D.S., M.P.H., Chief, Dental Disease Prevention Activity, CPS, CDC, Atlanta, Georgia
Lawrence Garfinkel, Vice President for Epidemiology and Statistics, Director of Cancer Prevention, American Cancer Society, Inc., New York, New York
Barbara A. Gilewitz, M.D., Professor and Chairman, Department of Dermatology, Boston University Medical Center, Boston, Massachusetts
Frederick K. Goodwin, M.D., Administrator, Alcohol, Drug Abuse, and Mental Health Administration, Rockville, Maryland
Robert O. Greer, Jr., D.D.S., Sc.D., Professor and Chairman, Division of Oral Pathology and Oncology, Department of Diagnostic and Biological Sciences, School of Dentistry, University of Colorado Health Sciences Center, Boulder, Colorado
Ellen Gritz, Ph.D., Director, Division of Cancer Control, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California
Nancy J. Haley, Ph.D., Associate Chief, Division of Nutrition and Endocrinology, American Health Foundation, Valhalla, New York

Sharon M. Hall, Ph.D., Professor of Medical Psychology, Department of Psychiatry, University of California, San Francisco, San Francisco Veterans Administration Medical Center, San Francisco, California

Robert Harmon, M.D., Administrator, Health Resources and Services Administration, Rockville, Maryland

Jeffrey E. Harris, M.D., Ph.D., Associate Professor, Department of Economics, Massachusetts Institute of Technology, Cambridge, Massachusetts, Clinical Associate, Medical Services, Massachusetts General Hospital, Boston, Massachusetts

Norman O. Harris, D.D.S., M.S., University of Texas Health Science Center, San Antonio, Texas

Jack Henningfield, Ph.D., Chief, Clinical Pharmacology Branch, National Institute on Drug Abuse Addiction Research Center, National Institutes of Health, Baltimore, Maryland

Robert A. Hiatt, M.D., Ph.D., Senior Epidemiologist, Division of Research, Kaiser Permanente Medical Care Program, Oakland, California

Milicent Higgins, M.D., Associate Director, Epidemiology and Biometry Program, Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland

Carol Hoguc, Ph.D., M.P.H., Director, Division of Reproductive Health, CCDPHP, CDC, Atlanta, Georgia

John Holbrook, M.D., Professor of Internal Medicine, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah

Richard Hunt, M.D., Division of Gastroenterology, McMaster University Medical Center, Hamilton, Ontario, Canada

Dwight Janerich, D.D.S., M.P.H., Professor of Epidemiology, Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut

William Kannel, M.D., Professor of Medicine, Department of Preventive Medicine, Boston University School of Medicine, Boston, Massachusetts

LTC James W. Kikendall, M.D., Assistant Chief, Gastroenterology Section, Walter Reed Army Medical Center, Washington, D.C.

Dushanka V. Kleinman, D.D.S., M.Sc.D., Section Chief, National Institute on Dental Research, National Institutes of Health, Bethesda, Maryland

C. Everett Koop, M.D., Sc.D., U.S. Surgeon General, 1981–89, Bethesda, Maryland

Jeffrey P. Koplan, M.D., M.P.H., Director, CCDPHP, CDC, Atlanta, Georgia

Lewis H. Kuller, M.D., Dr.P.H., Professor and Chairperson, Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania

Charles L. LeMaistre, M.D., President, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Claude Lenfant, M.D., Director, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland

Richard J. Levine, M.D., M.S., M.P.H., Chief Epidemiologist, Chemical Industry Institute of Toxicology, Research Triangle Park, North Carolina
Edward Lichtensrein, Ph.D., Research Scientist, Oregon Research Institute, Eugene, Oregon
Jay H. Lubin, Ph.D., National Cancer Institute, National Institutes of Health, Rockville, Maryland
Alfred C. Marcus, Ph.D., Director, Community Research and Applications, AMC Cancer Research Center, Denver, Colorado
Denis M. McCarthy, M.D., M.Sc., Chief, Division of Gastroenterology, University of New Mexico, Department of Medicine, Veterans Administration Medical Center, Albuquerque, New Mexico
J. Michael McGinnis, M.D., Deputy Assistant Secretary for Health, Disease Prevention and Health Promotion, Department of Health Human Services, Washington, D.C.
Sonja M. McKinlay, Ph.D., M.Sc., M.A., B.A., ASA, APHA, AER, SCt, Biometrics Society, Institute of Mathematical Statistics, International Menopause Society, American Association for the Advancement of Science, President, New England Research Institute, Inc., Watertown, Massachusetts
Robert E. Mecklenberg, D.D.S., M.P.H., Potomac, Maryland
L. Joseph Melton, III, M.D., Head, Section of Clinical Epidemiology, Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, Minnesota
Anthony Miller, B.A., M.B.B., M.R.C.P., M.F.C.M., F.R.C.P.C., Professor, Department of Preventive Medicine and Biostatistics, University of Toronto, Toronto, Ontario, Canada
Gregory Morosco, Ph.D., M.P.H., Chief, Health Education Branch and Coordinator, Smoking Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
Richard L. Naeye, M.D., Professor and Chairman, Department of Pathology, Pennsylvania State University School of Medicine, Hershey, Pennsylvania
Thomas A. Pearson, M.D., M.P.H., Ph.D., Director, Mary Imogene Bassett Research Institute, Cooperstown, New York, Professor of Public Health in Medicine, Columbia University, New York, New York
Terry Pechacek, Ph.D., Acting Chief, Smoking, Tobacco, and Cancer Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
Michael G. Perri, Ph.D., Professor and Deputy Chairman, Psychology Department, Fairleigh Dickinson University, Teaneck, New Jersey
Richard Peto, FRS, ICRF Cancer Studies Unit, Oxford, United Kingdom
John M. Pinney, Executive Director, Institute for the Study of Smoking Behavior and Policy, John F. Kennedy School of Government, Harvard University, Cambridge, Massachusetts
William F. Raub, Ph.D., Acting Director, National Institutes of Health, Bethesda, Maryland
Patrick L. Remington, M.D., Bureau of Community Health Prevention, Wisconsin Division of Health, Madison, Wisconsin
Everett R. Rhoades, M.D., Director, Indian Health Service, Rockville, Maryland
Julius Richmond, M.D., John D. MacArthur Professor of Health Policy, Emeritus, Division of Health Policy, Research, and Education, Harvard University, Boston, Massachusetts
The editors also acknowledge the contributions of the following staff members and others who assisted in the preparation of this Report:

Carmen Aguirre, Secretary, Office on Smoking and Health, CCDPHP, CDC, Rockville, Maryland
Andrea Anderson, Student Intern, Office on Smoking and Health, CCDPHP, CDC, Rockville, Maryland
Margaret Anglin, Secretary, Office on Smoking and Health, CCDPHP, CDC, Rockville, Maryland
Cathy Arney, Graphic Artist, The Circle, Inc., McLean, Virginia
Michele Asrael, Conference Coordinator, The Circle, Inc., McLean, Virginia
John L. Bagrosky, Associate Director for Program Operations, Office on Smoking and Health, CCDPHP, CDC, Rockville, Maryland
Sonia Balakirsky, Secretary, Office on Smoking and Health, CCDPHP, CDC, Rockville, Maryland
Barbara Barnes, Administrative Assistant, The Circle, Inc., McLean, Virginia
Carol A. Bean, Ph.D., Acting Managing Editor, Artemis Technologies, Inc., Springfield, Virginia
Marissa A. Bernstein, Editor, The Circle, Inc., McLean, Virginia
Em’Ria Briscoe, Conference Coordinator, The Circle, Inc., McLean, Virginia
Karen Broder, Public Information Specialist, Office on Smoking and Health, CCDPHP, CDC, Rockville, Maryland
Barbara M. Brown, Editorial Assistant, Office on Smoking and Health, Rockville, Maryland
Catherine E. Burckhardt, Public Information Specialist, Office on Smoking and Health, CCDPHP, CDC, Rockville, Maryland
Won Choi, Research Assistant, Office on Smoking and Health, CCDPHP, CDC, Rockville, Maryland
Trish Davidson, Student Intern, Office on Smoking and Health, CCDPHP, CDC, Rockville, Maryland
Susan E. Day, Secretary, Office on Smoking and Health, CCDPHP, CDC, Rockville, Maryland
Karen M. Deasy, Associate Director for Policy, Office on Smoking and Health, CCDPHP, CDC, Rockville, Maryland
June Dow, Public Health Service Congressional Reports Coordinator, Office of Health Planning and Evaluation, Office of the Assistant Secretary for Health, Washington, D.C.
Pam Edwards, System Administrator, MSA, Inc., Rockville, Maryland
Rita Elliott, Technical Editor, New Mexico Tumor Registry, University of New Mexico, Albuquerque, New Mexico
Seth Emont, Ph.D., Epidemic Intelligence Service Officer, Office on Smoking and Health, CCDPHP, CDC, Rockville, Maryland
Margaret E. Pickerel, Public Information and Publications Specialist, Office on Smoking and Health, CCDPHP, CDC, Rockville, Maryland
Elizabeth Precup, Student Intern, Office on Smoking and Health, CCDPHP, CDC, Rockville, Maryland
Dick Ray, Director of Computer Services, The Circle, Inc., McLean, Virginia
Nancy J. Rhodes, Editor, The Circle, Inc., McLean, Virginia
Rose Mary Romano, Chief, Public Information Branch, Office on Smoking and Health, CCDPHP, CDC, Rockville, Maryland
Sel Semler, Secretary, Office on Smoking and Health, CCDPHP, CDC, Rockville, Maryland
James Sliwa, Student Intern, Office on Smoking and Health, CCDPHP, CDC, Rockville, Maryland
Mattie Smith, Secretary, CCDPHP, CDC, Rockville, Maryland
Linda R. Spiegelman, Administrative Officer, Office on Smoking and Health, CCDPHP, CDC, Rockville, Maryland
Triton C. Stallings, Project Secretary, The Circle, Inc., McLean, Virginia
Sophia Stewart, Student Intern, Office on Smoking and Health, CCDPHP, CDC, Rockville, Maryland
Anne Trontell, M.D., Epidemic Intelligence Service Officer, Office on Smoking and Health, CCDPHP, CDC, Rockville, Maryland
Godfrey R. Vaz, M.D., Student Intern, Office on Smoking and Health, CCDPHP, CDC, Rockville, Maryland
Elyse Watson, Administrative Assistant, New Mexico Tumor Registry, University of New Mexico, Albuquerque, New Mexico
Michael F. White, Associate Director for Program Development, CCDPHP, CDC, Rockville, Maryland
Charles Wiggins, M.S.P.H., Epidemiologist, New Mexico Tumor Registry, University of New Mexico, Albuquerque, New Mexico
Louise G. Wiseman, Technical Information Specialist, Office on Smoking and Health, CCDPHP, CDC, Rockville, Maryland
Rebecca B. Wolf, Program Analyst, Office of Program Planning and Evaluation, CDC, Atlanta, Georgia
S. Tanner Wray, Technical Information Specialist, Office on Smoking and Health, CCDPHP, CDC, Rockville, Maryland
TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreword</td>
<td>1</td>
</tr>
<tr>
<td>Preface</td>
<td>5</td>
</tr>
<tr>
<td>Acknowledgments</td>
<td>xiii</td>
</tr>
<tr>
<td>List of Tables</td>
<td>xxv</td>
</tr>
<tr>
<td>List of Figures</td>
<td>xxxi</td>
</tr>
<tr>
<td>1. Introduction, Overview, and Conclusions</td>
<td>1</td>
</tr>
<tr>
<td>2. Assessing Smoking Cessation and Its Health Consequences</td>
<td>17</td>
</tr>
<tr>
<td>3. Smoking Cessation and Overall Mortality and Morbidity</td>
<td>71</td>
</tr>
<tr>
<td>4. Smoking Cessation and Respiratory Cancers</td>
<td>103</td>
</tr>
<tr>
<td>5. Smoking Cessation and Nonrespiratory Cancers</td>
<td>143</td>
</tr>
<tr>
<td>6. Smoking Cessation and Cardiovascular Disease</td>
<td>187</td>
</tr>
<tr>
<td>7. Smoking Cessation and Nonmalignant Respiratory Diseases</td>
<td>275</td>
</tr>
<tr>
<td>8. Smoking Cessation and Reproduction</td>
<td>367</td>
</tr>
<tr>
<td>9. Smoking, Smoking Cessation, and Other Nonmalignant Diseases</td>
<td>425</td>
</tr>
<tr>
<td>10. Smoking Cessation and Body Weight Change</td>
<td>469</td>
</tr>
<tr>
<td>11. Psychological and Behavioral Consequences and Correlates of Smoking Cessation</td>
<td>517</td>
</tr>
<tr>
<td>Volume Appendix. National Trends in Smoking Cessation</td>
<td>579</td>
</tr>
<tr>
<td>Glossary</td>
<td>617</td>
</tr>
<tr>
<td>Index</td>
<td>619</td>
</tr>
</tbody>
</table>
LIST OF TABLES

Chapter 2

Table 1. Measures of false reports of not smoking from studies using nicotine and cotinine as a marker .................................................. 38
Table 2. Measures of false reports from studies using CO as a marker .... 41
Table 3. Examples of potential methodologic problems in investigating the health consequences of smoking cessation ......................... 47

Chapter 3

Table 1. Summary of longitudinal studies of overall mortality ratios relative to never smokers among male current and former smokers according to duration of abstinence (when reported) ......................... 76
Table 2. Overall mortality ratios among current and former smokers, relative to never smokers, by sex and duration of abstinence at date of enrollment, ACS CPS-II ........................................... 78
Table 3. Estimated probability of dying in the next 16.5-year interval for quitting at various ages compared with never smoking and continuing to smoke, by amount smoked and sex ........................................ 83
Table 4. Summary of overall mortality ratios in intervention studies in which smoking cessation was a component ............................... 84
Table 5. Summary of studies of medical care utilization among smokers and former smokers ......................................................... 88
Table 6. Relation of smoking cessation to various measures of general health status ................................................................. 90
Table 7. Age- and sex-specific mortality rates among never smokers, continuing smokers, and former smokers by amount smoked and duration of abstinence at time of enrollment for subjects in ACS CPS-II study who did not have a history of cancer, heart disease, or stroke and were not sick at enrollment ........................................... 95
Table 8. Estimated probability of dying in the next 16.5-year interval (95% CI) for quitting at various ages compared with never smoking and continuing to smoke, by amount smoked and sex ................................. 97
Chapter 4

Table 1. Histologic changes (%) in bronchial epithelium by smoking status .................................................. 109
Table 2. Relative risks of lung cancer among never, former, and current smokers in selected epidemiologic studies ................................................................. 111
Table 3. Lung cancer mortality ratios among never, current, and former smokers by number of years since stopped smoking (relative to never smokers), prospective studies ............................................... 112
Table 4. Relative risks of lung cancer among former smokers, by number of years since stopped smoking, and current smokers, from selected case-control studies .................................................. 115
Table 5. Relative risks of lung cancer among never, current, and former smokers, by number of years since stopping smoking and histologic type .................................................. 119
Table 6. Relative risks of lung cancer among never, former, and current smokers by types of tobacco products smoked .................................................. 120
Table 7. Standard mortality ratios of lung cancer among former smokers in ACS CPS-II (relative to never smokers) by years of smoking abstinence, daily cigarette consumption at time of cessation, and history of chronic disease .................................................. 130
Table 8. Histologic changes in laryngeal epithelium by smoking status .................................................. 132
Table 9. Relative risks of laryngeal cancer by smoking status .................................................. 133

Chapter 5

Table 1. Studies of oral cancer and smoking cessation .................................................. 148
Table 2. Studies of esophageal cancer that have examined the effect of smoking cessation .................................................. 153
Table 3. Studies of cancer of the pancreas and smoking cessation .................................................. 156
Table 4. Studies of bladder cancer and smoking cessation .................................................. 160
Table 5. Bladder cancer risk according to smoking dose, duration of smoking, and smoking status .................................................. 165
Table 6. Studies of cervical cancer and smoking cessation .................................................. 167
Table 7. Studies of breast cancer and smoking cessation .................................................. 170
Table 8. Studies of cancer at selected sites that have examined the effect of smoking cessation .................................................. 173
Chapter 6

Table 1. Case-control studies of CHD risk among former smokers ........... 201
Table 2. Cohort studies of CHD risk among former smokers ............... 206
Table 3. Estimated probability of dying from ischemic heart disease in
the next 16.5-year interval (95% CI) for quitting at various ages
compared with never smoking and continuing to smoke, by amount
smoked and sex ................................................................. 216
Table 4. Intervention trials of smoking cessation and CHD risk ............ 225
Table 5. Studies of the effect of smoking cessation on persons with
diagnosed CHD ................................................................. 231
Table 6. Studies of smoking cessation and risk of death due to aortic
aneurysm ........................................................................ 242
Table 7. Case-control studies of smoking cessation and risk of stroke .... 247
Table 8. Prospective cohort studies of smoking cessation and risk of
stroke ............................................................................. 253

Chapter 7

Table 1. Percentages of subjects in cross-sectional studies with
respiratory symptoms, by cigarette smoking status and gender .......... 289
Table 2. Percentages of subjects in cross-sectional surveys with
respiratory symptoms by smoking and occupational exposure status ..... 297
Table 3. Change (%) in presence of respiratory symptoms, longitudinal
studies, by cigarette smoking status ............................................ 300
Table 4. Percentage of subjects with respiratory symptoms by smoking
status, 1961 and 1971, in a cohort of middle-aged, rural Finns .......... 305
Table 5. Age-standardized mortality ratios for influenza and pneumonia
for current and former smokers compared with never smokers .......... 309
Table 6. Association between cigarette smoking status and FEV₁ levels
in selected cross-sectional studies of adult populations ..................... 311
Table 7. Spirometric studies of participants in smoking cessation
programs ............................................................................. 320
Table 8. Studies of closing volume (CV/VC%), closing capacity
(CC/TLC%), and slope of alveolar plateau (SBN₂/L) among
participants in smoking cessation programs .................................... 324
Table 9. Population-based longitudinal studies of annual decline in
pulmonary function .................................................................. 330
Table 10. Decline of FEV₁ (mL/yr) in subjects in the Copenhagen City
Heart Study ........................................................................... 337
Table 11. Mortality attributable to COPD, United States, 1986 .............. 342
Table 12. Prospective studies of COPD mortality in relation to cigarette smoking status ........................................ 343
Table 13. Standardized mortality ratios for COPD among current and former smokers broken down by years of abstinence ......................... 346

Chapter 8

Table 1. Possible mechanisms for effect of smoking on pregnancy and pregnancy outcome .................................................. 372
Table 2. Summary of studies of fertility among smokers and former smokers ................................................................. 375
Table 3. Summary of studies of perinatal and neonatal mortality in smokers and nonsmokers during pregnancy .................. 377
Table 4. Estimated relative risk of fetal plus infant mortality for maternal smoking in several birthweight groups, adjusting for maternal marital status, education, age, and parity .......................... 378
Table 5. Summary of studies of perinatal mortality in smokers throughout pregnancy, smokers who quit in the early months of pregnancy, and nonsmokers during pregnancy .................................. 379
Table 6. Summary of studies of mean birthweight, by smoking status .... 382
Table 7. Summary of nonexperimental studies of smoking cessation after conception, mean increase (+) or decrease (−) in birthweight (g) according to timing of cessation ........................................ 384
Table 8. Summary of nonexperimental studies of relative risk of low birthweight for smoking cessation after conception ........ 385
Table 9. Summary of birthweight outcome in randomized trials of smoking cessation in pregnancy ........................................ 388
Table 10. Smoking and smoking cessation during pregnancy, summary of results of two surveys of national probability samples ........ 391
Table 11. Patterns of smoking cessation during pregnancy among selected populations .................................................... 394
Table 12. Summary of studies that estimated relative risk of various pregnancy outcomes for smoking based on a "synthesis" of the literature, and attributable risk percent based on several estimates of the prevalence of smoking during pregnancy ................................. 395
Table 13. Summary of studies reporting relationship of cigarette smoking and age at natural menopause .......................... 397
Table 14. Summary of studies of age of natural menopause among former smokers .......................................................... 399
Table 15. Sexual performance among male former smokers .................. 404
Table 16. Sperm quality among smokers and nonsmokers .................. 406
Table 17. Estimated relative risk of azoospermia or oligospermia among smokers versus nonsmokers or never smokers. 408
Table 18. Sperm quality among former smokers. 409

Chapter 9
Table 1. Percentage of healed duodenal ulcers among smoking and nonsmoking patients. 434
Table 2. Results of statistical analysis of pooled data from Table 1. 437
Table 3. Recurrences of duodenal ulcer in smokers and nonsmokers in clinical trials. 438
Table 4. Recurrences of gastric ulcer in smokers and nonsmokers in clinical trials. 442
Table 5. Summary of studies of smoking and bone mass. 445
Table 6. Summary of case-control studies of smoking and fractures. 450
Table 7. Summary of cohort studies of smoking and fractures. 454

Chapter 10
Table 1. Summary of prospective studies on smoking and body weight. 474
Table 2. Details of prospective studies in which change in weight relative to continuing smokers was reported. 477
Table 3. Mortality ratios for all ages combined in relation to the death rate of those 90–109% of average weight. 493
Table 4. Mortality ratios for all ages combined according to smoking status in relation to those 90–109% of average age. 494

Chapter 11
Table 1. Diagnostic categorization and criteria for nicotine withdrawal—Nicotine-induced organic mental disorder. 522
Table 2. Prospective studies of quitting-related changes in mood, anxiety, stress reactivity, perceived stress, self-image, and psychological well-being. 536
Table 3. Summary of data from 1985 NHIS, behaviors of never, former, and current smokers aged 20 and older. 548
Table 4. Summary of data from 1987 NHIS, behaviors of never, former, and current smokers aged 18 and older. 549
Table 5. Summary of data from 1987 BRFSS, behaviors of former smokers and current smokers aged 18 and older. 550
Table 6. Summary of data from 1987 BRFSS behaviors of former smokers aged 18 and older by duration of abstinence

Table 7. Percent distribution of persons aged 18 and older by tobacco product and use status, according to gender and cigarette smoking status, United States, 1987

Table 8. Physician visits and medical tests within the past year among AARP members aged 50 and older, by smoking status

Volume Appendix

Table 1. Quit ratio in selected States, by age group and gender—BRFSS, 1988

Table 2. Cigarette smoking continuum by year, percentage of ever cigarette smokers, by NHISs, United States, 1978–87, adults aged 20 and older

Table 3. Trends in quit ratio (%) (percentage of ever cigarette smokers who are former cigarette smokers), by age and by education, NHISs, United States, 1965–87, adults aged 20 and older

Table 4. Effect of adjusting for use of other tobacco products on quit ratio (percentage of ever cigarette smokers who are former cigarette smokers), 1987, NHIS, United States

Table 5. Selected measures of quitting activity (%), NHISs, United States, adults aged 20 and older

Table 6. Percentage of those intending to smoke in 5 years, by gender, AUTSs, United States, 1964–86, current smokers aged 21 and older

Table 7. Percentage who report having ever received advice to quit from a doctor, by smoking status and gender, United States, 1964–87, adults aged 21 and older
LIST OF FIGURES

Chapter 2
Figure 1. Cyclical model of the stages of change ........................................... 23
Figure 2. Hypothetical examples of disease incidence rates for current, former, and never smokers, by age ................................................................. 55

Chapter 3
Figure 1. Compared with never smokers, relative risk of mortality in current and former smokers aged 50–54, 60–64, and 70–74 at enrollment, by amount smoked and duration of abstinence .......................... 81
Figure 2. Estimated probability of dying in the next 16.5-yr interval for quitting at ages 55–59 compared with never smoking and continuing to smoke, by sex .......................................................... 98

Chapter 4
Figure 1. Risk of lung cancer by number of cigarettes smoked per day before quitting, number of years of abstinence, sex, and histologic types ... 121
Figure 2. Relative risk of lung cancer among ex-smokers compared with continuing smokers as a function of time since stopped smoking, estimated from logistic regression model, pattern adjusted for smoking duration compared with pattern unadjusted for duration ................. 123
Figure 3. Incidence of bronchial carcinoma among continuing cigarette smokers in relation to age and duration of smoking and among never smokers in relation to age, double logarithmic scale ......................... 127

Chapter 6
Figure 1. Hypothetical effects of smoking cessation on risk of CHD if mechanisms are predominantly rapidly reversible ....................................... 198
Figure 2. Estimated relative risk of MI after quitting smoking among men under age 55, adjusted for age ................................................................. 204
Figure 3. Mortality ratios due to coronary artery diseases; rates for men who have stopped smoking are compared with those for men who never smoked and those for men still smoking in 1952 ......................... 214
Figure 4. Mortality ratios for all cardiovascular diseases and CHD, by daily cigarette consumption, US Veterans Study, 1954–69 ......................... 219
Figure 5. Mortality ratio for current and former cigarette smokers by years of smoking cessation, US Veterans Study, 1954–69 ......................... 220
Figure 6. Effect of smoking cessation on survival among men with documented coronary atherosclerosis; pooled survival among quitters (N=1,490) and continuers (N=2,675) ........................................ 238

Figure 7. Mortality ratios for stroke for current smokers and ex-smokers compared with never smokers, by daily cigarette consumption, US Veterans Study, 1954–69 ........................................ 252

Figure 8. Survival free of stroke in cigarette smokers, never smokers, and former smokers, aged 60, using Cox proportional hazard regression model, among men and women ........................................ 259

Chapter 7

Figure 1. Nonproportional Venn Diagram of the interrelationship among chronic bronchitis, emphysema, asthma, and airways obstruction .......... 280

Figure 2. Theoretical curves depicting varying rates of decline of FEV1 .......... 281

Figure 3. Hypothesized mechanisms by which airway hyperresponsiveness may be associated with developing or established COPD without necessarily being a preexisting risk factor ............... 284

Figure 4. Symptom ratio (number of observed symptoms to number of possible symptoms) in nonmodifiers, modifiers, and quitters at each test period: symptoms are cough, sputum production, wheezing, and shortness of breath ........................................ 287

Figure 5. Prevalence of cough and phlegm by smoking group ............... 293

Figure 6. Prevalence of dyspnea by smoking group ............... 295

Figure 7. Sex-specific mean height-adjusted FEV1 residuals versus pack-years for current and ex-smokers, and distributions of number of subjects by pack-years ........................................ 317

Figure 8. Mean values FVC and FEV1, expressed as a percentage of predicted values, in 15 quitters and 42 smokers during 30 months after 2 smoking cessation clinics ........................................ 322

Figure 9. Mean values for the ratio of CV/VC, of CC/TLC, and slope for phase III of the single breath N2 test (N2/L), expressed as a percentage of predicted values in 15 quitters and 42 smokers during 30 months after 2 smoking cessation clinics ........................................ 326

Figure 10. Percent-predicted diffusing capacity (%pDL) by pack-years of smoking, current smokers and former smokers, in a study of adults in Tucson, AZ ........................................ 329

Figure 11. Mean ΔFEV1 values in never smokers, consistent ex-smokers, subjects who quit smoking during followup, and consistent smokers in several age groups ........................................ 334

Figure 12. Effects of quitting smoking during followup among men aged 50–69 ........................................ 336
Chapter 8

Figure 1. Perinatal, neonatal, and fetal mortality rates by birthweight in singleton white males, 1980 ........................................ 380

Chapter 11

Figure 1. Performance on a meter (i.e., visual) vigilance task. Performance on the continuous clock task, a visual vigilance task .... 527

Figure 2. Self-reported withdrawal discomfort among abstinent smokers .... 531

Figure 3. Drinking relative to smoking status for men, 1983 NHIS .......... 558

Figure 4. Drinking relative to smoking status for women, 1983 NHIS .......... 559

Appendix

Figure 1. Trends in the quit ratio. United States, 1965–87, by gender ........ 590

Figure 2. Trends in the quit ratio. United States, 1965–87, by race ........ 591

Figure 3. Flow chart of quitting history, attempts lasting longer than 1 year. NHEFS ...................................................... 597

Figure 4. Estimated duration of abstinence on first 1-year or longer quit attempt, product-limit method, N=3,363 .................. 598

Figure 5. Percentage of ever smokers who never tried to quit, by education, United States, 1974–87 ........................................... 601

Figure 6. Percentage of persons smoking at 12 months prior to the survey interview who quit for at least 1 day during those 12 months, United States, 1978–80, 1987, by education ................................. 602

Figure 7. Percentage of ever smokers who had been abstinent for less than 1 year. United States, 1966–87, by education .................. 603

Figure 8. Percentage of ever smokers who had been abstinent for 1–4 years. United States, 1966–87, by education ................................. 604

Figure 9. Percentage of ever smokers who had been abstinent for 5 years or more. United States, 1966–87, by education .................. 605